Cryptococcosis Market: An insight on the important factors and trends influencing the market

The global cryptococcosis market has been foretold by the analysts at Transparency Market Research (TMR) to be pioneered by a small number of companies rooted in the developed geographies of the world. Holding an extremely fragmented nature, the global cryptococcosis market had Janssen Biotech, Inc., Bristol-Myers Squibb Company, Valeant Pharmaceuticals, Inc., and Pfizer, Inc. secure a combined 41.0% share in 2015.

 Leading players have been expected to sustain their dominance in the global cryptococcosis market by adhering to factors such as lofty investments in research and development and enhanced brand name recognition. Proliferation of operations in developed regions which bear higher awareness and demand could also a strategy adopted by players to cement their status in the global cryptococcosis market.

Read Full Report: http://www.transparencymarketresearch.com/cryptococcosis-market.html

 According to a market intelligence report released by TMR, the global cryptococcosis market has been forecasted to reach a valuation of US$6.2 bn by 2024 from US$4.31 bn in 2016 at a CAGR of 4.8% between 2016 and 2024. By treatment, the global cryptococcosis market has been foreseen to witness the flucytosine segment earn revenue at a higher CAGR of 5.4% during the forecast period. North America could dominate the global cryptococcosis market with an exact 50.0% share by 2024.

 Deathly Fungal Illness Makes a Killing for Cryptococcosis Market

 The basic factor that has been prognosticated to work in the favor of the global cryptococcosis market is the rising number of patients infected by the fatal fungal disease. The healthcare sector is aware of the fact that cryptococcosis is spreading at an alarming rate across the world, which could benefit the global cryptococcosis market. Players in the global cryptococcosis market may be aware that the Centers for Disease Control and Prevention (CDC) has spotted the disease to be responsible for a 625,000 death count and close to a 1.0 mn new cases. Amphotericin B plus oral flucytosine, presently the golden yardstick for cryptococcosis treatment, has been projected to be in the vanguard of the demand in the global cryptococcosis market.

 Government efforts directed toward the development of pipeline drugs, availability of advanced treatment alternatives, and improvement in the distribution of existing drugs have been prophesied to propel the growth in the global cryptococcosis market. With last-stage HIV patients developing the disease, the demand in the global cryptococcosis market could increase further.

 Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14984

 Towering Mortality Puts Brakes on Research and Development in Cryptococcosis Market

 The significantly high mortality rate of patients with the disease could be one of critical aspects of the cutback in growth of the global cryptococcosis market. The authors of the global cryptococcosis market report have pointed out cryptococcal meningitis and pneumocystis pneumonia as the top two fungal infections causing deaths worldwide. Moreover, HIV patients diagnosed with cryptococcosis combine a nearly 100.0% mortality rate, which could be menacing for the global cryptococcosis market. Thus, it has been envisaged that the global cryptococcosis market will have a very little scope for developing pipeline as well as existing drugs. Consequently, the gush of generics and impending patient expirations could degrade the demand in the global cryptococcosis market.

 Howbeit, the analysts envision the global cryptococcosis market to repair its growth as integrated facilities are installed in regions with an all-time high penetration potential. As a result, pharmaceutical competitors in the global cryptococcosis market could sustain their position while augmenting production speeds and curbing operational costs. Mergers and acquisitions and strong investment inflow have also been anticipated to set the tone for the global cryptococcosis market.

 The information presented in this review is based on a Transparency Market Research report, titled, “Cryptococcosis Market (Treatment - Amphotericin B (Amphocin and Fungizone), Flucytosine (Ancobon), Fluconazole (Diflucan), Voriconazole, and Surgery Treatment; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Store, and Mail Order Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Cryptococcosis Market: An insight on the important factors and trends influencing the market

Cryptococcosis, also known as cryptococcal disease is a potentially fatal fungal disease. It is caused by inhalation of an encapsulated yeast called Cryptococcus neoformans. Cryptococcosis is believed to be acquired by inhalation of the infectious propagule from the environment. Although the exact nature of the infectious propagule is unknown, the leading hypothesis is the basidiospore created through sexual or asexual reproduction.

Cryptococcosis market: Types of infection

There are three identified Cryptococcus strains that causes disease worldwide namely Cryptococcus neoformans, Cryptococcus grubii and Cryptococcus gattii. Exposure via respiratory or the gastrointestinal tract are considered as the most common and opportunistic pathway for the organism entry in the host. Cryptococcus neoformans can be found worldwide in soil, birds, animals and humans. Whereas, alternative route of administration can be through transplant of infected tissue, surgical instrument or laboratory instruments. Cryptococcosis neoformans can affect a person’s lungs causing pneumonia, or central nervous system causing meningitis.

Read Full Report: http://www.transparencymarketresearch.com/cryptococcosis-market.html

People with impaired immunity, such as cancer or AIDS patients that acquire the cryptococcosis illness are predominantly infected with the C. neoformans and C. grubii, while C. gattii can cause illness in not only immunocompromised individuals but also among healthy individuals. In between 1999 and 2010, 281 cases of C. gattii have been reported to the British Columbia Centre for Disease Control among animals and human residing in Vancouver Island and surrounding areas within Canada and the northwest United States.

Cryptococcosis market: Treatment

With the availability highly active antiretroviral therapy (HAART), the management of cryptococcosis has become a combination of established antifungal treatments together with treatment of any other associated disease. Although the prevalent use of HAART has lowered the incidences of cryptococcosis in medically developed countries yet the incidences and mortality due to infection is still high in regions having limited access to healthcare, HAART and uncontrolled HIV disease. AIDS associated Cryptococcosis accounts for 50 percent of all Cryptococcal infections reported annually and usually occurs in HIV patients when their CD4 lymphocyte count is below 200/mm3.

Cryptococcosis market: Segmentation

Market for Cryptococcosis can be segmented on the basis of anatomical location that is central nervous system, Cryptococcosis of bone and so on and risk groups which included HIV infected and organ transplant individual.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14984

In 2000, the Infectious Diseases Society of America (IDSA) first published Practice Guidelines for the Management of Cryptococcal Disease based on clinical data evidences and expert opinion to manage and curb down the highly recognizable invasive fungal pathogen. However, over the past decade a series of new clinical issues and host risk groups have arisen which demands for revision of guideline to proper and efficient management of cryptococcosis.

The major symptoms of cryptococcosis include fever, malaise, excessive coughing mental status changes and vision defects. Till date there are no novel drug or vaccines available specifically to treat cryptococcosis.

Cryptococcosis market: Regions and key players

Human disease is endemic in Australia, parts of Africa, the Mediterranean region, Papua New Guinea, India, Southern California, Mexico, Brazil, Paraguay and south-east Asia. Some of the organization/ research centers working on the development of vaccine/drug include Pfizer Inc., Janssen Pharmaceutical, Inc., Johnson & Johnson, MedStar Health Research Institute among others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.